Ishida T, Kaneko S, Akazawa K, Tateishi M, Sugio K, Sugimachi K
Department of Surgery II, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Cancer Res. 1993 Oct 15;53(20):5000-3.
Cell proliferation in 211 primary non-small cell lung carcinomas was assessed by using an immunostaining of proliferating cell nuclear antigen (PCNA) and a silver staining of argyrophilic nucleolar organizer region (Ag-NOR). More than 5% PCNA positive cells was designated PCNA(+), and less than 5% was PCNA(-). A mean number or more of the Ag-NOR was a high Ag-NOR count, and less than the mean number was a low Ag-NOR count. The proportion of the tumors with PCNA(+) and high Ag-NOR counts showed an increase in patients in an advanced stage of the disease (P < 0.05). In 125 patients with stage I disease, the 5-year survival rate was 20% in patients with PCNA(+) and high Ag-NOR counts, compared with 47% in those with either PCNA(+) or high Ag-NOR counts and 76% in those with PCNA(-) and low Ag-NOR counts (P < 0.05). Our data suggest that the tumors with PCNA(+) and high Ag-NOR counts have a high proliferative activity. The combination analysis of PCNA and Ag-NOR may be useful in assessing prognosis in lung cancer, even in stage I disease.
通过增殖细胞核抗原(PCNA)免疫染色和嗜银核仁组织区(Ag-NOR)银染色,对211例原发性非小细胞肺癌的细胞增殖情况进行评估。PCNA阳性细胞超过5%被定义为PCNA(+),低于5%为PCNA(-)。Ag-NOR的平均数及以上为高Ag-NOR计数,低于平均数为低Ag-NOR计数。疾病晚期患者中PCNA(+)且Ag-NOR计数高的肿瘤比例增加(P < 0.05)。在125例I期疾病患者中,PCNA(+)且Ag-NOR计数高的患者5年生存率为20%,而PCNA(+)或Ag-NOR计数高的患者为47%,PCNA(-)且Ag-NOR计数低的患者为76%(P < 0.05)。我们的数据表明,PCNA(+)且Ag-NOR计数高的肿瘤具有高增殖活性。PCNA和Ag-NOR的联合分析可能有助于评估肺癌预后,即使在I期疾病中也是如此。